We are live on ! Find out more
CCXI

ChemoCentryx, Inc.

Delisted

CCXI was delisted on the 19th of October, 2022.

182 hedge funds and large institutions have $1.44B invested in ChemoCentryx, Inc. in 2022 Q2 according to their latest regulatory filings, with 39 funds opening new positions, 72 increasing their positions, 52 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

292% more call options, than puts

Call options by funds: $40.3M | Put options by funds: $10.3M

200% more funds holding in top 10

Funds holding in top 10: 13 (+2)

38% more repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 52

30% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 30

3% more funds holding

Funds holding: 176182 (+6)

3% more capital invested

Capital invested by funds: $1.4B → $1.44B (+$40.7M)

Holders
182
Holders Change
+6
Holders Change %
+3.41%
% of All Funds
3.07%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.05%
New
39
Increased
72
Reduced
52
Closed
30
Calls
$40.3M
Puts
$10.3M
Net Calls
+$30M
Net Calls Change
+$12.9M
Name Holding Trade Value Shares
Change
Change in
Stake
AAP
176
Arax Advisory Partners
Colorado
$1K +$154 +7 +25%
HR
177
Howe & Rusling
New York
$1K +$419 +19 +95%
Rockefeller Capital Management
178
Rockefeller Capital Management
New York
$1K +$1.43K +65 New
Bank of Montreal
179
Bank of Montreal
Ontario, Canada
$213 -$12.7K -574 -7%
APM
180
Avidity Partners Management
Texas
-$29.5M -1,175,000 Closed
RCM
181
RA Capital Management
Massachusetts
-$29M -1,155,964 Closed
MCM
182
Moore Capital Management
New York
-$8.38M -334,250 Closed
WP
183
Woodline Partners
California
-$5.09M -203,093 Closed
CM
184
Caption Management
Oklahoma
-$2.86M -129,789 Closed
FAM
185
Fred Alger Management
New York
-$2.25M -89,828 Closed
MS
186
Maven Securities
Jersey
-$2.17M -86,638 Closed
Simplex Trading
187
Simplex Trading
Illinois
-$1.34M -60,695 Closed
BAM
188
Blueshift Asset Management
New Jersey
-$1.29M -51,600 Closed
Federated Hermes
189
Federated Hermes
Pennsylvania
-$1.23M -49,161 Closed
MPAM
190
Monarch Partners Asset Management
Massachusetts
-$1.14M -45,570 Closed
BCM
191
Bluefin Capital Management
New York
-$893K -35,614 Closed
TI
192
Trexquant Investment
Connecticut
-$878K -35,024 Closed
Walleye Capital
193
Walleye Capital
New York
-$869K -34,651 Closed
Man Group
194
Man Group
United Kingdom
-$711K -28,356 Closed
HT
195
HAP Trading
New York
-$409K -18,536 Closed
CCIA
196
Campbell & Co Investment Adviser
Maryland
-$447K -17,827 Closed
HighTower Advisors
197
HighTower Advisors
Illinois
-$334K -13,161 Closed
LFAS
198
Level Four Advisory Services
Texas
-$326K -13,016 Closed
EGM
199
Engineers Gate Manager
New York
-$320K -12,780 Closed
FRM
200
Fox Run Management
Connecticut
-$214K -8,546 Closed

CCXI Hedge Fund Activity: Q2 2022 in Review

182 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in ChemoCentryx, Inc. (CCXI) for Q2 2022, worth a combined $1.44B — up 2.9% from $1.4B a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new CCXI positions and 30 closed out — a net gain of 9 holders — while 72 added to existing stakes and 52 trimmed.

The largest buyer was Hood River Capital Management, opening a new position worth an estimated $29.5M. The largest seller was Avidity Partners Management, exiting entirely with an estimated $29.5M sold.

  • 182 institutional investors held ChemoCentryx, Inc. (CCXI) as of Q2 2022, up from 176 in Q1 2022.
  • Funds reported $1.44B of ChemoCentryx, Inc. stock for Q2 2022, up 2.9% quarter-over-quarter.
  • 39 funds opened new ChemoCentryx, Inc. positions in Q2 2022 and 30 closed out, a net change of +9 holders.
  • The largest ChemoCentryx, Inc. buyer in Q2 2022 was Hood River Capital Management, an estimated $29.5M added.
  • The largest ChemoCentryx, Inc. seller in Q2 2022 was Avidity Partners Management, an estimated $29.5M sold.

Based on aggregated 13F filings for Q2 2022.